Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: JAMA Dermatol. 2020 Sep 1;156(9):1004–1011. doi: 10.1001/jamadermatol.2020.1729

Table 2.

Summary of Published Studies Using Other GEP Platforms

Source GEP test Patients Findings Test performance
Meves et al13 CP-GEP • Development cohort: 360 patients • CP model: AUC, 0.78 (95% CI, 0.73-0.83)
• CP-GEP model: AUC, 0.89 (95% CI, 0.85-0.93; P < .001); HR, 17.32 (95% CI, 8.02-37.41)a 		• Sensitivity: 89%b
• Specificity: 76% (cutoff point 0.1)
• Validation cohort: 146 patients
• 4 Centers
 • 50% Stage I
 • 18% Stage II
 • 32% Stage III		 • CP model: AUC, 0.68 (95% CI, not reported)
• CP-GEP model: AUC, 0.93 (95% CI, 0.87-0.97)c 		• Sensitivity: 100%
• Specificity: 80%
• Stage-specific breakdown not reportedd
Mulder et al14,e CP-GEP • 211 Patients; single center
 • 24% T1
 • 43% T2
 • 33% T3
• 27.5% SLNB positive		 • SLNB reduction rate: 40% • T1-T3: NPV, 89%b
• T1-T2: NPV, 91%
• Complete stage-specific breakdown not reportedf
Gambichler et al37,e 8-GEP • 203 Patients; 2 centers
• Stages IA-IIIC		 • High GRS: 5-y 70% RFS (HR, 2.40; 95% CI, 1.18-4.89; P = .015)g
• SLNB positive: 5-y 65% RFS (HR, 2.11; 95% CI, 1.02-4.37; P = .046)		 • GRS plus SLNB: sensitivity of relapse detection increased from 38.7% (SLNB alone) to 67.7%
• Stage-specific breakdown not reportedh
Amaral et al38 8-GEP • 245 Patients
 • 48% Stage IIA
 • 32% Stage IIB
 • 20% Stage IIC
• >2-y f/u		 • High GRS: 5-y 82% MSS (HR, 1.55; 95% CI, 1.13-2.13; P = .006)g • GRS found to add value to AJCCi classification in defining both low-risk and high-risk patients

Abbreviations: AJCC, American Joint Committee on Cancer; AUC, area under the curve; CP, clinicopathologic, f/u, follow-up; GEP, gene expression profile; GRS, gene expression risk score; HR, hazard ratio; MSS, melanoma-specific survival; NPV, negative predictive value; RFS, recurrence-free survival; SLNB, sentinel lymph node biopsy.

a

Multivariate Cox regression analysis based on 360 cases with complete data for age, tumor ulceration, Breslow thickness, SLNB result, and molecular factors (4 genes in original GEP group).

b

For predicting SLNB positivity.

c

Multivariate Cox regression analysis based on 146 cases with complete data for age, Breslow thickness, SLNB result, and molecular factors (8 genes, including 2 from original GEP group).

d

Patients diagnosed from 2000 to 2014; AJCC edition used for staging not reported.

e

Only the abstract was available for review.

f

Patients diagnosed from 2007 to 2017; AJCC edition used for staging not reported.

g

Multivariate analysis that included tumor thickness, age, and GRS.

h

Years of diagnosis and AJCC edition used for staging were not reported.

i

Patients diagnosed from 2000 to 2016; AJCC edition used for staging not reported.